Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00995904 · ClinicalTrials.gov registry record · Phase 2
Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00995904 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 25 participants.
The verdict
NCT00995904, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This Phase 2 study was to investigate the tolerability of unit dose budesonide (MAP0020) at three doses in pediatric volunteers with a diagnosis and history of mild-to-moderate stable asthma and evaluate the pharmacokinetic profile of budesonide resulting from inhalation aerosol delivery.
Interventions
- DRUG 84ug MAP0020
- DRUG 42ug MAP0020
- DRUG 21ug MAP0020
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2009-09 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00995904
The ClinicalTrials.gov registry entry for NCT00995904 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 84ug MAP0020 is the first listed.
NCT00995904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00995904 about?
NCT00995904 is a clinical study titled "Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma". This Phase 2 study was to investigate the tolerability of unit dose budesonide (MAP0020) at three doses in pediatric volunteers with a diagnosis and history of mild-to-moderate stable asthma and evaluate the pharmacokinetic profile of budesonide resulting from inhalation aerosol delivery.
What is the current status of trial NCT00995904?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2009-09. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00995904?
The interventions under investigation include: 84ug MAP0020 (DRUG), 42ug MAP0020 (DRUG), 21ug MAP0020 (DRUG).
Who is sponsoring clinical trial NCT00995904?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.